Perrigo Company PLC PERRIGO ORD S.../  IE00BGH1M568  /

London Domestic
9/29/2022  4:51:24 PM Chg. - Volume Bid6:00:11 AM Ask6:00:11 AM Market Capitalization Dividend Y. P/E Ratio
35.72USD - 96
Turnover: 3,436.48
-Bid Size: - -Ask Size: - 4.92 bill.USD 2.63% -

Business description

Perrigo Company plc, a top five global over-the-counter ("OTC") consumer goods and pharmaceutical company, offers patients and customers high quality products at affordable prices. From its beginnings in 1887 as a packager of generic home remedies, Perrigo, headquartered in Ireland, has grown to become the world's largest manufacturer of OTC products and supplier of infant formulas for the store brand market. The Company is also a leading provider of generic extended topical prescription products and receives royalties from Multiple Sclerosis drug Tysabri®. Perrigo provides Quality Affordable Healthcare Products® across a wide variety of product categories and geographies primarily in North America, Europe, and Australia, as well as other markets, including Israel, China and Latin America.
 

Management board & Supervisory board

CEO
Murray S. Kessler
Management board
Raymond Silcock, Grainne Quinn, James E. Dillard III, Rob Willis, Ron Janish, Svend Andersen, Todd W. Kingma, Tom Farrington
Supervisory board
Rolf Classon, Adriana Karaboutis, Bradley Alford, Donal O'Connor, Erica L. Mann, Geoffrey M. Parker, Jeff Kindler, Katherine Doyle, Murray S. Kessler, Orlando D. Ashford, Theodore R. Samuels
 

Company data

Name: Perrigo Company plc
Address: Treasury Building, Lower Grand Canal St.,IRL-Dublin 2, Ireland
Phone: +1-353-1709-4000
Fax: -
E-mail: -
Internet: www.perrigo.com/
Industry: Healthcare
Sector: Pharmaceutical Industry
Sub sector: Pharmaceuticals
End of financial year: 12/31
Free Float: 67.70%
IPO date: -

Investor relations

Name: Bradley Joseph
IR phone: +1-269-686-3373
IR Fax: -
IR e-mail: bradley.joseph@perrigo.com

Main Shareholders

Freefloat
 
67.70%
T. Rowe Price Associates, Inc.
 
13.20%
The Vanguard Group
 
11.50%
BlackRock Inc.
 
7.60%